Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania

The introduction in clinical practice of selective cyclin-dependent kinase (CDK) 4/6 inhibitors improves the outcome of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). In Romania, the three available CDK 4/6 inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Miron, Andreea-Iuliana, Anghel, Alexandra-Valentina, Barnonschi, Andrei-Alexandru, Mitre, Ruxandra, Liscu, Horia-Dan, Găinariu, Estera, Pătru, Raluca, Coniac, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252356/
https://www.ncbi.nlm.nih.gov/pubmed/37296790
http://dx.doi.org/10.3390/diagnostics13111938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252356/
https://www.ncbi.nlm.nih.gov/pubmed/37296790
http://dx.doi.org/10.3390/diagnostics13111938

Ejemplares similares